Heart failure & cardiomyopathies
The Inflation Reduction Act and Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Disease
Authors' conclusion
The IRA will reduce Medicare beneficiaries' out-of-pocket drug costs for the selected cardiovascular conditions by 8% to 87%.
Study context
- Population
- Medicare Part D beneficiaries with severe hypercholesterolemia, heart failure with reduced ejection fraction (HFrEF), HFrEF with atrial fibrillation (AF), or cardiac transthyretin amyloidosis
- Participants
- 4,137 Part D plans
- Comparison
- Projected out-of-pocket costs under Inflation Reduction Act (IRA) provisions vs 2022 baseline
- Outcome
- Projected annual out-of-pocket drug costs per condition
Methodological detailsnationwide
- Nationwide
Main finding
As reported in the abstract
Mean projected annual out-of-pocket costs
| Group | Severe hypercholesterolemia | HFrEF | HFrEF with AF | Amyloidosis | Hypercholesterolemia | Cardiac transthyretin amyloidosis |
|---|---|---|---|---|---|---|
| 2022 | $1,629 | $2,758 | $3,259 | $14,978 | ||
| 2024 | $2,855 (12% reduction) | $3,468 (77% reduction) | ||||
| 2025 | $1,954 (29% reduction) | $2,000 (39% reduction) | $1,491 (8% reduction) | $2,000 (87% reduction) |
Severe hypercholesterolemia
2022$1,629
2024— not stated in the abstract
2025— not stated in the abstract
HFrEF
2022$2,758
2024— not stated in the abstract
2025$1,954 (29% reduction)
HFrEF with AF
2022$3,259
2024$2,855 (12% reduction)
2025$2,000 (39% reduction)
Amyloidosis
2022$14,978
2024$3,468 (77% reduction)
2025— not stated in the abstract
Hypercholesterolemia
2022— not stated in the abstract
2024— not stated in the abstract
2025$1,491 (8% reduction)
Cardiac transthyretin amyloidosis
2022— not stated in the abstract
2024— not stated in the abstract
2025$2,000 (87% reduction)
Original publication
The Inflation Reduction Act and Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Disease. J Am Coll Cardiol. Published 30 May 2023. doi:10. 1016/ j. jacc. 2023. 03. 414
Composed by AI from the published abstract and checked against it. How Briefs are made →